Motus GI Holdings logo
Motus GI Holdings MOTS
report update icon

Quarterly report 2024-Q1
added 05-16-2026

Motus GI Holdings Cash Flow 2023-2011 | MOTS

Brief overview of Motus GI Holdings's cash generation

The comparison covers five available annual reports between 2019 and 2023.

Operating cash flow ended negative at -$11.2 million. Core operations are not yet producing a sustainable inflow.

Core operations generated cash in 0 of five years. Frequent negative periods raise financial risk.

Cash flow takeaway

Motus GI Holdings's cash profile looks stretched: weak operating cash flow limits investment, payouts and debt-servicing capacity.

Annual Cash Flow Motus GI Holdings

2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Operating Cash Flow

-11.2 M -17.5 M -14.4 M -17 M -19.9 M -14.9 M -10.4 M - - - - - -

Depreciation & Amortization

451 K 510 K 439 K 377 K 223 K 152 K 65 K - - - - - -

Accounts Receivables

76 K 59 K 109 K 35 K 65 K 5 K - - - - - - -

Total Inventories

496 K 999 K 496 K 805 K 1.01 M 23 K 6 K - - - - - -

All numbers in USD currency

Quarterly Cash Flow Motus GI Holdings

2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Operating Cash Flow

-2.02 M - -9.34 M -7.37 M -4.8 M - -13.4 M -9.81 M -5.25 M - -10.5 M -7.6 M -4.54 M - -14 M -11.3 M -7.15 M - -14.4 M -9.76 M -5.59 M - -10.5 M -7.28 M -3.48 M - -7.62 M -4.66 M -2.22 M - - - - - - - - - - - - - - - - - - - - - - - -

Depreciation & Amortization

95 K - 111 K 113 K 117 K - 128 K 129 K 124 K - 318 K 102 K 98 K - 154 K 125 K 76 K - 58 K 51 K 48 K - 106 K 62 K 26 K - 42 K 25 K 9 K - - - - - - - - - - - - - - - - - - - - - - - -

Accounts Receivables

81 K 76 K 102 K 106 K 52 K 59 K 161 K 81 K 18 K 109 K 181 K 73 K 74 K 35 K 39 K 10 K 19 K 65 K 5 K 8 K 1 K 5 K 23 K 31 K 11 K 5 K - 5 K 5 K - - - - - - - - - - - - - - - - - - - - - - - -

Total Inventories

479 K 496 K 781 K 823 K 798 K 999 K 1.01 M 1.04 M 700 K 496 K 515 K 706 K 770 K 805 K 1.3 M 1.32 M 1.23 M 1.01 M 771 K 93 K 115 K 23 K 46 K 81 K 21 K 6 K 6 K 6 K 6 K - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Cash Flow Statement is one of the three key financial reports of the company Motus GI Holdings, reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.

Main Sections of the Cash Flow Statement
  • Operating Activities
    This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash.
  • Investing Activities
    Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign.
  • Financing Activities
    Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.

The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.

Cash flow statements of other stocks in the Diagnostics research sector

Issuer Price % 24h Market Cap Country
Enzo Biochem Enzo Biochem
ENZ
- -8.98 % $ 14.8 K usaUSA
Heska Corporation Heska Corporation
HSKA
- - $ 1.31 B usaUSA
DermTech DermTech
DMTK
- -11.32 % $ 2.94 M usaUSA
Centogene N.V. Centogene N.V.
CNTG
- -6.23 % $ 30.6 M germanyGermany
Neogen Corporation Neogen Corporation
NEOG
$ 9.4 2.29 % $ 2.04 B usaUSA
Natera Natera
NTRA
$ 253.82 0.63 % $ 34.7 B usaUSA
Akumin Akumin
AKU
- -17.87 % $ 25.9 M canadaCanada
Celcuity Celcuity
CELC
$ 83.26 0.97 % $ 3.89 B usaUSA
Aspira Women's Health Aspira Women's Health
AWH
- -6.19 % $ 10.5 M usaUSA
Accelerate Diagnostics Accelerate Diagnostics
AXDX
- -61.36 % $ 2.46 M usaUSA
Koninklijke Philips N.V. Koninklijke Philips N.V.
PHG
$ 26.1 2.19 % $ 24.7 B niderlandNiderland
Biocept Biocept
BIOC
- -13.05 % $ 7.29 M usaUSA
Personalis Personalis
PSNL
$ 11.73 -1.26 % $ 1.05 B usaUSA
Co-Diagnostics Co-Diagnostics
CODX
$ 1.51 7.09 % $ 2.01 M usaUSA
Chembio Diagnostics Chembio Diagnostics
CEMI
- 0.22 % $ 16.8 M usaUSA
Check-Cap Ltd. Check-Cap Ltd.
CHEK
- - $ 9.42 M israelIsrael
HTG Molecular Diagnostics HTG Molecular Diagnostics
HTGM
- -20.0 % $ 1.06 M usaUSA
Global Cord Blood Corporation Global Cord Blood Corporation
CO
- - $ 399 M chinaChina
Genetic Technologies Limited Genetic Technologies Limited
GENE
- - $ 7.1 B australiaAustralia
Neuronetics Neuronetics
STIM
$ 1.82 -2.67 % $ 120 M usaUSA
Genetron Holdings Limited Genetron Holdings Limited
GTH
- 0.12 % $ 80.1 M chinaChina
Exact Sciences Corporation Exact Sciences Corporation
EXAS
- - $ 19.8 B usaUSA
CareDx, Inc CareDx, Inc
CDNA
$ 35.41 -0.95 % $ 1.89 B usaUSA
NeoGenomics NeoGenomics
NEO
$ 15.27 13.96 % $ 1.96 B usaUSA
QIAGEN N.V. QIAGEN N.V.
QGEN
- - $ 10.6 B niderlandNiderland
Soleno Therapeutics Soleno Therapeutics
SLNO
- - $ 2.69 B usaUSA
Waters Corporation Waters Corporation
WAT
$ 379.48 -1.15 % $ 22.6 B usaUSA
Medpace Holdings Medpace Holdings
MEDP
$ 584.93 2.44 % $ 16.9 B usaUSA
Quest Diagnostics Incorporated Quest Diagnostics Incorporated
DGX
$ 235.22 -0.31 % $ 26.1 B usaUSA
Exagen Exagen
XGN
$ 4.35 -2.25 % $ 93.8 M usaUSA
Biomerica Biomerica
BMRA
$ 1.59 -0.62 % $ 3.65 M usaUSA
Invitae Corporation Invitae Corporation
NVTA
- - $ 21.2 M usaUSA
Organovo Holdings Organovo Holdings
ONVO
- -2.3 % $ 19.4 M usaUSA
DarioHealth Corp. DarioHealth Corp.
DRIO
$ 7.1 -5.27 % $ 28.3 M israelIsrael
OpGen OpGen
OPGN
- -16.95 % $ 1.54 M usaUSA
Anixa Biosciences Anixa Biosciences
ANIX
$ 3.48 -1.14 % $ 113 K usaUSA
PerkinElmer PerkinElmer
PKI
- -0.91 % $ 14.7 B usaUSA
DexCom DexCom
DXCM
$ 75.14 0.39 % $ 29.3 B usaUSA
OPKO Health OPKO Health
OPK
$ 1.37 -17.27 % $ 1.03 B usaUSA
Psychemedics Corporation Psychemedics Corporation
PMD
- -1.84 % $ 15.3 M usaUSA
ICON Public Limited Company ICON Public Limited Company
ICLR
$ 178.18 -1.14 % $ 14 B irlandaIrlanda
Quotient Limited Quotient Limited
QTNT
- -11.32 % $ 1.1 M schweizSchweiz
T2 Biosystems T2 Biosystems
TTOO
- -39.35 % $ 313 K usaUSA
Renalytix AI plc Renalytix AI plc
RNLX
- 5.66 % $ 22.7 M britainBritain
Syneos Health Syneos Health
SYNH
- - $ 4.46 B usaUSA